Ramino-Bio is developing treatments for cardiometabolic diseases by enhancing branched-chain amino acid (BCAA) catabolism.
Chronically elevated levels of circulating BCAAs are known to be a propagating factor for cardiac hypertrophy, muscle lipid accumulation, hepatic lipid storage, and glycemia, which contribute to various metabolic disorders. Ramino-Bio is developing a drug for lowering elevated BCAA levels.
Maple syrup urine disease, Heart failure with preserved ejection fraction
Prof. Yibin Wang, Inventor
Dorit Cohen-Carmon, PhD, CSO